Attending the #AACR26 Session on Optimizing Efficacy While Limiting Toxicity in Immunotherapy for Cancer Treatment? Don't miss this work identifying unique features of checkpoint inhibitor–induced colitis that involves session speaker Michael Dougan. https://t.co/vrwRUudU8a https://t.co/kmkLszxUde